RCKT - Rocket Pharmaceuticals, Inc.
| Previous Close | 14.28 |
| Open | 14.12 |
| Bid | 13.93 x 1100 |
| Ask | 14.08 x 1300 |
| Day's Range | 13.67 - 14.12 |
| 52 Week Range | 10.75 - 25.86 |
| Volume | 10,334 |
| Avg. Volume | 341,867 |
| Market Cap | 688.263M |
| Beta (3Y Monthly) | 2.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.85 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.17 |
- Business Wire
Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces the publication of long-term data from the ongoing Phase 1/2 trial of RP-L102, the Company’s lentiviral vector (LVV)-based gene therapy for Fanconi Anemia (FA) in the journal Nature Medicine. Follow-up for each of the initial four patients was 18-30 months from administration of RP-L102. “Data from our first trial of RP-L102 demonstrate increasing levels of bone marrow engraftment, leading to stabilization and restored bone marrow function.
- Business Wire
Rocket Pharmaceuticals Announces Registration-Enabling Phase 2 Plans for RP-L102 Gene Therapy for Fanconi Anemia Following a Supportive End-of-Phase 1 FDA Meeting
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces the U.S. Phase 2 clinical development plan for RP-L102, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA). “We are thankful for the Agency’s collaboration and guidance on the Phase 2 study design which will enable an efficient registration path to potentially bring our first-in-class gene therapy to market for FA patients in need.
- Business Wire
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces participation at the following upco
- Business Wire
Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia
—Phase 2 Trial to Commence Patient Enrollment in Europe—
- Business Wire
Rocket Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
- First Patient Dosed in RP-A501 Trial for Danon Disease -
- Insider Monkey
Here’s What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT)
We at Insider Monkey have gone over 738 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article, we look at what those funds think of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) based on that […]
- Simply Wall St.
A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Does the June share price for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) reflect what it's really worth? Today, we...
- Business Wire
Rocket Pharmaceuticals Announces Patient Dosing Has Commenced in Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease. University of California San Diego (UCSD) Health is the initial and lead center for the Phase 1 clinical trial under the leadership of Eric Adler, M.D., Director of Cardiac Transplant and Mechanical Circulatory Support at UC San Diego Health and Professor of Medicine at University of California, San Diego School of Medicine and Barry Greenberg, M.D. Dr. Greenberg is the Director of the Advanced Heart Failure Treatment Program at UC San Diego Health and Professor of Medicine at UC San Diego School of Medicine, and is principal investigator of the trial.
- Business Wire
Rocket Pharmaceuticals Sponsors 3rd Annual PKD Patients’ Forum
Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform clinical-stage gene therapy company, today sponsors the 3rd Annual Pyruvate Kinase Deficiency Day in Madrid, Spain, a day devoted to patients, families, clinicians and global scientific experts.
- Simply Wall St.
Did You Manage To Avoid Rocket Pharmaceuticals's (NASDAQ:RCKT) 19% Share Price Drop?
While not a mind-blowing move, it is good to see that the Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) share price has...
- Associated Press
Rocket Pharmaceuticals: 1Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 43 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
- Business Wire
Rocket Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
– Initiated Phase 1 Trial for FA “Process B” Using a Modified Cell Enrichment Process, Transduction Enhancers, and Commercial-Grade Vector Manufacturing and Cell Processing –
- Business Wire
Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference
Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Wednesday, May 15, 2019, at 3:40p.m.
- Business Wire
Rocket Pharmaceuticals Presents Preclinical Data of RP-A501 for Danon Disease at the American Society of Gene and Cell Therapy 2019 Annual Meeting
- Biodistribution of RP-A501 Demonstrates High Concentration in Heart, the End-Organ Target in Danon Disease -
- Business Wire
Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM)
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that the California Institute for Regenerative Medicine (CIRM) has awarded Rocket a $6.5mm CLIN2 grant award to support the clinical development of gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I). The CIRM was founded in 2004 following the passing of Proposition 71 or the California Stem Cell Research and Cures Initiative, which allocated $3 billion in state funding for stem cell research conducted in California.
- Business Wire
Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 675,000 additional shares of its common stock, at a public offering price of $17.50 per share. Rocket intends to use the net proceeds from this offering to further fund the development of its pipeline of gene therapies for rare diseases, to accelerate the buildout of in-house manufacturing capabilities, and for general corporate purposes. SVB Leerink, Evercore ISI and William Blair acted as joint-bookrunning managers for the offering.
- Benzinga
The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...
- Business Wire
Rocket Pharmaceuticals Prices Public Offering of Common Stock
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $17.50 per share. Rocket has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock. All the shares in the offering are to be sold by Rocket.
- Business Wire
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that it has commenced an underwritten public offering of shares of its common stock. Rocket also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All the shares in the offering are to be sold by Rocket.
- Business Wire
Rocket Pharmaceuticals Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
- 4 oral presentations and 3 poster presentations focus on Rocket’s clinical and preclinical programs -
- Business Wire
Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces one oral poster presentation and two poster presentations at the upcoming American College of Cardiology 2019 Annual Meeting being held March 16-18, 2019 in New Orleans, LA. RP-A501 is the Company’s first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of California San Diego School of Medicine (UCSD). UCSD Health will be the initial and lead center for the planned Phase 1 clinical trial.
- Simply Wall St.
Are Insiders Selling Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share pricesRead More...
- Business Wire
Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S.
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that the first patient has been dosed in the open-label, Phase 1 clinical trial of RP-L102, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA). The clinical trial will evaluate “Process B” RP-L102 which incorporates a modified cell enrichment process, transduction enhancers, and commercial-grade vector manufacturing and cell processing.
